# Checkpoint Therapeutics

Source: https://onco.cc/companies/checkpoint-therapeutics/  
OnCo record `checkpoint-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Checkpoint Therapeutics developed cosibelimab, an anti-PD-L1 antibody approved by the FDA in December 2024 for advanced cutaneous squamous cell carcinoma, and was acquired by Sun Pharma in 2025.

## Summary

Checkpoint Therapeutics, a Massachusetts company founded within Fortress Biotech, developed cosibelimab (Unloxcyt), an anti-PD-L1 antibody with an intact Fc region designed to add antibody-dependent cell killing to checkpoint blockade. The FDA approved it in December 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma not curable by surgery or radiation, after an earlier complete response letter over a manufacturing site. Sun Pharma agreed to acquire the company in 2025. Company facts are from the official website and FDA approval records.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Checkpoint Therapeutics, Inc.
- Tags: fda-oce-applicant
- HQ: Waltham, MA
- Type: biotech
- Website: https://www.checkpointtherapeutics.com/

## Sources

- Official website: https://www.checkpointtherapeutics.com/
- FDA: oncology and hematologic malignancies approval notifications: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications

## Connected records

- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Cosibelimab](https://onco.cc/drugs/cosibelimab/)
- trials: [CK-301-101](https://onco.cc/trials/ck-301-101/), [Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC](https://onco.cc/trials/nct04786964/)
- key papers: [Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma](https://onco.cc/key-papers/paper-ck-301-101-jitc-2023/)

---
JSON: https://onco.cc/api/v1/entities/checkpoint-therapeutics.json